Morgan Stanley on Eli Lilly (LLY): 'the incremental volume from vials could prove to be a positive offset'
Tweet Send to a Friend
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,106.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
